What is the correct way and dosage of militizumab?

Mirikizumab is mainly used clinically to treat ulcerative colitis (UC) and Crohn's disease (CD). Its usage and dosage are slightly different in the two diseases. The administration method and dosage need to be accurately adjusted according to different stages (induction phase and maintenance phase) to achieve the best therapeutic effect.

For patients with ulcerative colitis, standard induction therapy with militizumab is an intravenous infusion of 300 mg militizumab three times at weeks 0, 4, and 8. Each infusion should take no less than 30 minutes to ensure even distribution of the drug and reduce the risk of acute infusion reactions. After completion of induction therapy, if the patient responds positively to militizumab, continuation of maintenance therapy is recommended. Starting from the 12th week, the maintenance phase uses subcutaneous injection, 200 mg each time, once every 4 weeks. This dose is usually achieved by injecting two consecutive 100 mg doses. Patients can inject themselves under the guidance of a doctor or be performed by a professional nurse to improve the convenience and compliance of treatment.

For patients with Crohn's disease, the dose of militizumab is relatively higher due to the more complex pathological mechanisms. During the induction period, intravenous infusion is recommended at weeks 0, 4, and 8, with each dose being 900 mg. The infusion time should not be less than 90 minutes to ensure safety and sustained efficacy. During the maintenance phase, subcutaneous injections of 300 mg are administered every 4 weeks starting at week 12. This 300 mg can be completed by injecting a combination of two doses (100 mg and 200 mg). There is no fixed order of injection, but a suitable plan needs to be formulated by professional medical personnel.

The treatment process of militizumab has staged characteristics: first, high doses are used to quickly suppress the inflammatory response, and then lower doses are used to continuously maintain the remission state. This design not only improves treatment efficiency, but also reduces potential risks caused by long-term immunosuppression. All patients should undergo regular evaluation during treatment, including liver and kidney function tests, inflammatory index monitoring, adverse drug reaction records, etc., to ensure medication safety.

Reference materials:https://omvoh.lilly.com/